Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML
Background Acute myeloid leukemia (AML) stem cells (LSCs) are capable of surviving current standard chemotherapy and are the likely source of deadly, relapsed disease. While stem cell transplant serves as proof-of-principle that AML LSCs can be eliminated by the immune system, the translation of exi...
Guardado en:
Autores principales: | R Eric Davis, Marina Konopleva, Natalia Baran, Gheath Al-Atrash, Naval Daver, Shelley Herbrich, Tianyu Cai, Connie Weng, Marisa J L Aitken, Sean M Post, Jared Henderson, Chunhua Shi, Guillame Richard-Carpentier, Guy Sauvageau, Keith Baggerly, Dongxing Zha, Ondrej Havranek |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ec9bd9e5fbea4ec3b2a31d083604c1bd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
TARGETED THERAPY IN AML TREATMENT
por: Giovanni Martinelli
Publicado: (2021) -
FLT3-ITD POSITIVITY IN AML; CASE SERIES
por: Kemal FİDAN
Publicado: (2021) -
Acta Nº200
por: Banco Central de Chile
Publicado: (2019) -
piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells
por: Zhicheng Du, et al.
Publicado: (2021) -
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML
por: Christina D. Drenberg, et al.
Publicado: (2019)